Please help support the development and maintenance of this educational site.
Donate at PayPal
1. Daugirdas, JT, Blake PG, Ing TS. Handbook of Dialysis.
Fifth ed. Philadelphia: Wolters Kluwer; 2015
2. Murphy JE. Clinical Pharmacokinetics. Third ed. Bethesda, MD. American Society
of Health-System Pharmacist; 2005.
3. Winter ME. Basic Clinical Pharmacokinetics. Third ed. Vancouver, WA. Applied Therapeutics; 1994
4. Schumacher GE.
Therapeutic Drug Monitoring. East Norwalk, Connecticut. Appleton & Lange; 1995
5. Burton ME. Applied Pharmacokinetics
& Pharmacodynamics.
Fourth ed. Baltimore, Md. Lippincott Williams & Wilkins. 2006
6. Evans WE. Applied Pharmacokinetics. Third ed.Vancouver,
WA. Applied Therapeutics; 1992
7. Mehvar R. Estimation of Pharmacokinetic
Parameters Based on The Patient-Adjusted Population Data. Am J Pharm Educ.
2006;70:96-114
8.
Pallotta KE, Manley H. Vancomycin Use in Patients Requiring Hemodialysis: A
literature Review. Seminars in Dialysis. 2007; 23:63-70
9. Vandecasteele SJ,
DeVriese AS. Vancomycin Doing in Patients on Intermittent Hemodialysis. Seminars
in Dialysis;24:50-55
10. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ. Vancomycin Redistribution: Dosing Recommendations Following High Flux Hemodialysis. Kidney Internationa;45:232-237
11.
Barth RH, DeVincenzo. Use of Vancomycin in High Flux Hemodialysis: Experience
with 130 Courses of Therapy. Kidney International. 1996;50:929-36
12. Brown
M, Polisetty R, Gracely EJ, Cuhaci B, Schlecht HP. Weight Based Loading of
Vancomycin In Patients on Hemodialysis. CID. 2011;53:164-66
13. Crew P, Heintz SJ, Heintz BH. Vancomycin Dosing and Monitoring for Patients with End-stage Renal Disease Receiving Intermittent Hemodialysis.
Am J Health-Syst Pharm 2015;72:1856-64
14.
Nyman HA, Agarwal A, Senekjian HO, Leypoldt JK, Cheung AK. Removal of Vancomycin
Administered During Dialysis by a High Flux Dialyzer. Hemodialysis
International. 2018;22:383-87
15.
Westra N, Prosst JH, Franssen CFM, Wilms EB, van Buren M, Touw DJ. Vancomycin
Pharmacokinetic Model Development in Patients on Intermittent Online Hemodiafiltration. PLoS One. 2019;14(5):e0216801.
Published 2019 May 14.
doi:10.1371/journal.pone.0216801
16.
Wesseloo R, Wierdsma NI, van Kamp IL. Lithium Dosing Strategies During Pregnancy
an the Postpartum Period. Br H Psychiatry. 2017;211(1):31-36
17.
Lobeck F. A review of Lithium Dosing Methods. Pharmacotherpy 2018;8(4):248-55
18.
Molenaar NM, Poels EM, Robakis T, Wesseloo R. Management of Lithium Dosing
Around Delivery: An Observational Study. Bipolar Disorders 2021;23:49-54
19. Beringer PM.
Winter's Basic Clinical Pharmacokinetics. Sixth Edition. Philadelphia Wolters
Kluwer. 2018
20. Murphy JE. Clinical Pharmacokinetics. Sixth Edition. ASHP
Publications. 2017
21. Burton ME. Applied Pharmacokinetics &
Pharmacodynamics. Fourth Edition. Lippincott Williams & Wilkins. 2006
22. Taylor WJ. A Textbook for the Clinical Application of Therapeutic Drug Monitoring.
Abbott Laboratories. 1986
23. Beringer PM. Winter's Basic Clinical Pharmacokinetics Sixth Edition Wolters
Kluwer
24. Murphy JE. Clinical Pharmacokinetics 7th Edition. ASHP 2022
25.
Beringer PM. Winter's Basic Clinical Pharmacokinetics Seventh Edition Wolters
Kluwer
26. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.Are vancomycin
trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.
27. Manjunath P Pai 1, Joseph Hong 2, Lynne Krop. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02490-16. doi: 10.1128/AAC.02490-16
28. Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E.
Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02042-17. doi: 10.1128/AAC.02042-17. Print 2018 Feb.
29.
Natalie A. Finch, Evan J. Zasowski, Kyle P. Murray, Ryan P. Mynatt, Jing J.
Zhao, Raymond Yost, Jason M. Pogue, Michael J. Rybak.
A Quasi-Experiment
To Study the Impact of Vancomycin Area under the Concentration-Time
Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity
Antimicrob
Agents Chemother. 2017 Dec; 61(12): e01293-17. Prepublished online 2017 Sep
18. Published online 2017 Nov 22. doi: 10.1128/AAC.01293-17
30. Thomas P
Lodise, Jr., Susan L Rosenkranz, Matthew Finnemeyer, Scott Evans, Matthew
Sims, Marcus J Zervos, C Buddy Creech, Pratish C Patel, Michael Keefer, Paul
Riska. The Emperor’s New Clothes: PRospective Observational Evaluation of
the Association Between Initial VancomycIn Exposure and Failure Rates Among
ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus
Bloodstream Infections (PROVIDE). Clinical Infectious Diseases, Volume 70,
Issue 8, 15 April 2020, Pages 1536–1545, https://doi.org/10.1093/cid/ciz460
31.
Manjunath P Pai, Michael Neely, Keith A Rodvold, Thomas P Lodise. Innovative
approaches to optimizing the delivery of vancomycin in individual patients
Adv Drug Deliv Rev . 2014 Nov 20:77:50-7. doi: 10.1016/j.addr.2014.05.016.
Epub 2014 Jun 5.
32. Nathan Fewel. Vancomycin area under the curves
estimated with pharmacokinetic equations using trough-only data
J Clin
Pharm Ther. 2021 Oct;46(5):1426-1432. doi: 10.1111/jcpt.13474. Epub 2021 Jun
25.
33. Abdullah Aljutayli, Daniel J G Thirion, Guillaume Bonnefois,
Fahima Nekka. Pharmacokinetic equations versus Bayesian guided vancomycin
monitoring: Pharmacokinetic model and model-informed precision dosing trial
simulations. Clin Transl Sci. 2022 Apr;15(4):942-953. doi:
10.1111/cts.13210. Epub 2022 Feb 15.
34. Bellamy A, Covington EW. Acute
Kidney Injury Incidence With Bayesian Dosing Software Versus 2-Level
First-Order Area Under the Curve-Based Dosing of Vancomycin With
Piperacillin-Tazobactam. J Pharm Technol. 2023 Aug;39(4):183-190. doi:
10.1177/87551225231182542. Epub 2023 Jun 27.
35. Jack Chang, Dhara Patel,
Ana Vega, Kimberly C Claeys, Emily L Heil, Marc H Scheetz. Does calculation
method matter for targeting vancomycin area under the curve? J Antimicrob
Chemother. 2022 Jul 28;77(8):2245-2250. doi: 10.1093/jac/dkac151.
36.
Pimonrat Chanapiwat, Taniya Paiboonvong, Pinyo Rattanaumpawan, Preecha
Montakantikul. Comparison of the mathematical equation and trapezoidal
approach for 24 h area under the plasma concentration-time curve calculation
in patients who received intravenous vancomycin in an acute care setting
Pharmacol Res Perspect.. 2023 Feb;11(1):e01046. doi: 10.1002/prp2.1046.
37.
Katie B Olney, Katie L Wallace, Ryan P Mynatt, David S Burgess, Kaitlyn
Grieves, Austin Willett, Johann Mani, Alexander H Flannery.
Comparison of
Bayesian-derived and first-order analytic equations for calculation of
vancomycin area under the curve.
Pharmacotherapy. 2022 Feb
17;42(4):284–291. doi: 10.1002/phar.2670
38. Jack Chang, Dhara Patel, Ana
Vega, Kimberly C Claeys, Emily L Heil 5, Marc H Scheetz. Does calculation
method matter for targeting vancomycin area under the curve? J Antimicrob
Chemother . 2022 Jul 28;77(8):2245-2250. doi: 10.1093/jac/dkac151.
39.
Evan J Zasowski, Kyle P Murray, Trang D Trinh, Natalie A Finch, Jason M
Pogue, Ryan P Mynatt, Michael J Rybak. Identification of Vancomycin
Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous
Vancomycin. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01684-17. doi:
10.1128/AAC.01684-17. Print 2018 Jan.
40. R Chavada 1, N Ghosh 2, I
Sandaradura 3 4, M Maley 5, S J Van Hal. Establishment of an AUC0-24
Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin
Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.
Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02535-16. doi:
10.1128/AAC.02535-16. Print 2017 May.
41. C Tyler Pitcock, Aric Schadler,
David S Burgess, Donna R Burgess, Sarah E Cotner, Jeremy Van Hoose, Eric R
Gregory, Katie L Wallace. Association of vancomycin-induced acute kidney
injury with trough versus AUC monitoring in patients receiving extended
durations of therapy. Antimicrob Steward Healthc Epidemiol. 2023 Dec
4;3(1):e225. doi: 10.1017/ash.2023.490.
42. Emily Abdelmessih, Nandini
Patel, Janaki Vekaria, Brynna Crovetto, Savanna SanFilippo, Christopher
Adams, Luigi Brunetti. Vancomycin area under the curve versus trough only
guided dosing and the risk of acute kidney injury: Systematic review and
meta-analysis. Pharmacotherapy 2022 Sep;42(9):741-753. doi:
10.1002/phar.2722. Epub 2022 Aug 5.
43. Tan Zhang, Elke H J Krekels,
Cornelis Smit, Eric P A van Dongen, Roger J M Brüggemann, Catherijne A J
Knibbe. How to Dose Vancomycin in Overweight and Obese Patients with Varying
Renal (Dys)function in the Novel Era of AUC 400-600 mg·h/L-Targeted Dosing.
Clin Pharmacokinet . 2024 Jan;63(1):79-91. doi: 10.1007/s40262-023-01324-5.
Epub 2023 Nov 16
44. Heather D'Amico, Katie L Wallace, Donna Burgess,
David S Burgess, Sarah Cotner, Ryan Mynatt, Nannan Li, Arnold Stromberg,
Jeremy VanHoose.
Acute Kidney Injury Associated with Area under the Curve
versus Trough Monitoring of Vancomycin in Obese Patients. Antimicrob Agents
Chemother.
2022 Jan 18;66(1):e0088621. doi: 10.1128/AAC.00886-21. Epub
2021 Oct 11.
45. Cornelis Smit, Roeland E Wasmann, Sebastiaan C Goulooze,
Marinus J Wiezer, Eric P A van Dongen, Johan W Mouton, Roger J M Brüggemann,
Catherijne A J Knibbe. Population pharmacokinetics of vancomycin in obesity:
Finding the optimal dose for (morbidly) obese individuals. Br J Clin
Pharmacol. . 2020 Feb;86(2):303-317. doi: 10.1111/bcp.14144. Epub 2020 Jan
7.
46. Fatima Khalifa Al-Sulaiti, Ahmed Mohamed Nader, Mohamed Omar Saad,
Adila Shaukat, Rakesh Parakadavathu, Ahmed Elzubair, Daoud Al-Badriyeh,
Hazem Elewa, Ahmed Awaisu. Clinical and Pharmacokinetic Outcomes of
Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring
Approaches: A Pragmatic Randomized Controlled Trial. Eur J Drug Metab
Pharmacokinet . 2019 Oct;44(5):639-652. doi: 10.1007/s13318-019-00551-1.
47.
Lucie Polášková , Irena Murínová, Jana Gregorová, Ondřej Slanař, Martin Šíma.
Vancomycin population pharmacokinetics and dosing proposal for the initial
treatment in obese adult patients. Front Pharmacol . 2024 Jun 4:15:1364681.
doi: 10.3389/fphar.2024.1364681. eCollection 2024.
48. Nyein Hsu Maung,
Janthima Methaneethorn, Thitima Wattanavijitkul, Tatta Sriboonruang.
Comparison of area under the curve for vancomycin from one- and
two-compartment models using sparse data. Eur J Hosp Pharm . 2022
Mar;29(e1):e57-e62. doi: 10.1136/ejhpharm-2020-002637. Epub 2021 Jul 20.
49.
Jialong Chen, Jing Lin, Jianzhen Weng, Yang Ju, Yanming Li. Association
between trough serum vancomycin concentration and vancomycin-associated
acute kidney injury and 30-day mortality in critically ill elderly adults.
BMC Infect Dis. 2024 Mar 20;24(1):330. doi: 10.1186/s12879-024-09227-x.
50.
Rashmi V Shingde, Garry G Graham, Stephanie E Reuter, Jane E Carland,
Richard O Day, Sophie L Stocker. Comparison of the Area Under the Curve for
Vancomycin Estimated Using Compartmental and Noncompartmental Methods in
Adult Patients With Normal Renal Function. Ther Drug Monit . 2019
Dec;41(6):726-731. doi: 10.1097/FTD.0000000000000690.